{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,22]],"date-time":"2026-03-22T05:11:24Z","timestamp":1774156284723,"version":"3.50.1"},"reference-count":14,"publisher":"Tohoku University Medical Press","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Tohoku J. Exp. Med."],"published-print":{"date-parts":[[2021]]},"DOI":"10.1620\/tjem.255.123","type":"journal-article","created":{"date-parts":[[2021,10,11]],"date-time":"2021-10-11T22:13:17Z","timestamp":1633990397000},"page":"123-126","source":"Crossref","is-referenced-by-count":6,"title":["Repeated In-Stent Restenosis Despite Aggressive Lipid Loweringby PCSK-9 Inhibitor Treatment: A Case Report"],"prefix":"10.1620","volume":"255","author":[{"given":"Yutaka","family":"Yonezawa","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Medicine, Dokkyo Medical University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masashi","family":"Sakuma","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Dokkyo Medical University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shichiro","family":"Abe","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Dokkyo Medical University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ikuko","family":"Shibasaki","sequence":"additional","affiliation":[{"name":"Department of Cardiac and Vascular Surgery, Dokkyo Medical University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeru","family":"Toyoda","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Dokkyo Medical University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teruo","family":"Inoue","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Dokkyo Medical University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"622","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"Cannon, C.P., Blazing, M.A., Giugliano, R.P., McCagg, A., White, J.A., Theroux, P., Darius, H., Lewis, B.S., Ophuis, T.O., Jukema, J.W., De Ferrari, G.M., Ruzyllo, W., De Lucca, P., Im, K., Bohula, E.A.,  et al. (2015)  Ezetimibe added to statin therapy after acute coronary syndromes.  <i>N. Engl. J. Med.<\/i>, 372, 2387-2397.","DOI":"10.1056\/NEJMoa1410489"},{"key":"2","doi-asserted-by":"crossref","unstructured":"Cannon, C.P., Braunwald, E., McCabe, C.H., Rader, D.J., Rouleau, J.L., Belder, R., Joyal, S.V., Hill, K.A.,  Pfeffer, M.A. &amp; Skene, A.M.; Pravastatin or Atorvastatin Evaluation Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators (2004)  Intensive versus moderate lipid lowering with statins after acute coronary syndromes.  <i>N. Engl. J. Med.<\/i>, 350, 1495-1504.","DOI":"10.1056\/NEJMoa040583"},{"key":"3","doi-asserted-by":"crossref","unstructured":"Cholesterol Treatment Trialists\u2019 (CTT) Collaboration; Baigent, C., Blackwell, L., Emberson, J., Holland, L.E., Reith, C., Bhala, N., Peto, R., Barnes, E.H., Keech, A.,  Simes, J. &amp; Collins, R. (2010)  Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials.  <i>Lancet<\/i>, 376, 1670-1681.","DOI":"10.1016\/S0140-6736(10)61350-5"},{"key":"4","doi-asserted-by":"crossref","unstructured":"de Lemos, J.A., Blazing, M.A., Wiviott, S.D., Lewis, E.F., Fox, K.A., White, H.D., Rouleau, J.L., Pedersen, T.R., Gardner, L.H., Mukherjee, R., Ramsey, K.E., Palmisano, J., Bilheimer, D.W., Pfeffer, M.A., Califf, R.M.,  et al. (2004)  Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial.  <i>JAMA<\/i>, 292, 1307-1316.","DOI":"10.1001\/jama.292.11.1307"},{"key":"5","doi-asserted-by":"crossref","unstructured":"Inoue, T. &amp; Node, K. (2006)  Vascular failure: a new clinical entity for vascular disease.  <i>J. Hypertens.<\/i>, 24, 2121-2130.","DOI":"10.1097\/01.hjh.0000249684.76296.4f"},{"key":"6","doi-asserted-by":"crossref","unstructured":"Inoue, T. &amp; Node, K. (2007) Statin therapy for vascular failure. <i>Cardiovasc. Drugs Ther.<\/i>, 21, 281-295.","DOI":"10.1007\/s10557-007-6038-y"},{"key":"7","doi-asserted-by":"crossref","unstructured":"LaRosa, J.C., Grundy, S.M., Waters, D.D., Shear, C., Barter, P., Fruchart, J.C., Gotto, A.M., Greten, H., Kastelein, J.J.,  Shepherd, J. &amp; Wenger, N.K.; Treating to New Targets (TNT) Investigators (2005)  Intensive lipid lowering with atorvastatin in patients with stable coronary disease.  <i>N. Engl. J. Med.<\/i>, 352, 1425-1435.","DOI":"10.1056\/NEJMoa050461"},{"key":"8","doi-asserted-by":"crossref","unstructured":"Pedersen, T.R., Faergeman, O., Kastelein, J.J., Olsson, A.G., Tikkanen, M.J., Holme, I., Larsen, M.L., Bendiksen, F.S., Lindahl, C.,  Szarek, M. &amp; Tsai, J.; Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study Group (2005)  High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial.  <i>JAMA<\/i>, 294, 2437-2445.","DOI":"10.1001\/jama.294.19.2437"},{"key":"9","doi-asserted-by":"crossref","unstructured":"Ridker, P.M., Danielson, E., Fonseca, F.A., Genest, J., Gotto, A.M. Jr., Kastelein, J.J., Koenig, W., Libby, P., Lorenzatti, A.J., MacFadyen, J.G., Nordestgaard, B.G., Shepherd, J.,  Willerson, J.T. &amp; Glynn, R.J.; JUPITER Study Group (2008)  Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.  <i>N. Engl. J. Med.<\/i>, 359, 2195-2207.","DOI":"10.1056\/NEJMoa0807646"},{"key":"10","doi-asserted-by":"crossref","unstructured":"Ridker, P.M., Everett, B.M., Thuren, T., MacFadyen, J.G., Chang, W.H., Ballantyne, C., Fonseca, F., Nicolau, J., Koenig, W., Anker, S.D., Kastelein, J.J.P., Cornel, J.H., Pais, P., Pella, D., Genest, J.,  et al. (2017)  Antiinflammatory therapy with canakinumab for atherosclerotic disease.  <i>N. Engl. J. Med.<\/i>, 377, 1119-1131.","DOI":"10.1056\/NEJMoa1707914"},{"key":"11","doi-asserted-by":"crossref","unstructured":"Ridker, P.M., Rifai, N., Clearfield, M., Downs, J.R., Weis, S.E.,  Miles, J.S. &amp; Gotto, A.M. Jr.; Air Force\/Texas Coronary Atherosclerosis Prevention Study Investigators (2001)  Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events.  <i>N. Engl. J. Med.<\/i>, 344, 1959-1965.","DOI":"10.1056\/NEJM200106283442601"},{"key":"12","doi-asserted-by":"crossref","unstructured":"Sabatine, M.S., Giugliano, R.P., Keech, A.C., Honarpour, N., Wiviott, S.D., Murphy, S.A., Kuder, J.F., Wang, H., Liu, T., Wasserman, S.M.,  Sever, P.S. &amp; Pedersen, T.R.; FOURIER Steering Committee and Investigators (2017)  Evolocumab and clinical outcomes in patients with cardiovascular disease.  <i>N. Engl. J. Med.<\/i>, 376, 1713-1722.","DOI":"10.1056\/NEJMoa1615664"},{"key":"13","doi-asserted-by":"crossref","unstructured":"Scandinavian Simvastatin Survival Study Group (1994)  Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S).  <i>Lancet<\/i>, 344, 1383-1389.","DOI":"10.1016\/S0140-6736(94)90566-5"},{"key":"14","doi-asserted-by":"crossref","unstructured":"Taguchi, I., Iimuro, S., Iwata, H., Takashima, H., Abe, M., Amiya, E., Ogawa, T., Ozaki, Y., Sakuma, I., Nakagawa, Y., Hibi, K., Hiro, T., Fukumoto, Y., Hokimoto, S., Miyauchi, K.,  et al. (2018)  High-dose versus low-dose pitavastatin in Japanese patients with stable coronary artery disease (REAL-CAD): a randomized superiority trial.  <i>Circulation<\/i>, 137, 1997-2009.","DOI":"10.1161\/CIRCULATIONAHA.117.032615"}],"container-title":["The Tohoku Journal of Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/tjem\/255\/2\/255_123\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,16]],"date-time":"2021-10-16T03:26:49Z","timestamp":1634354809000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/tjem\/255\/2\/255_123\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"references-count":14,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1620\/tjem.255.123","relation":{},"ISSN":["0040-8727","1349-3329"],"issn-type":[{"value":"0040-8727","type":"print"},{"value":"1349-3329","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021]]}}}